Oncotarget

Research Papers:

MYC overexpression with its prognostic and clinicopathological significance in breast cancer

Jingkun Qu, Xixi Zhao, Jizhao Wang, Xu Liu, Yan Yan, Lin Liu, Hui Cai, Hangying Qu, Ning Lu, Yuchen Sun, Feidi Wang, Jiansheng Wang _ and Jia Zhang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:93998-94008. https://doi.org/10.18632/oncotarget.21501

Metrics: PDF 1163 views  |   HTML 1884 views  |   ?  


Abstract

Jingkun Qu1,*, Xixi Zhao2,*, Jizhao Wang1, Xu Liu1, Yan Yan1, Lin Liu1, Hui Cai1,3, Hangying Qu4, Ning Lu4, Yuchen Sun5, Feidi Wang2, Jiansheng Wang1 and Jia Zhang1

1The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

2Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, P.R. China

3Department of Vascular Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

4Department of Oncological Surgery, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China

5Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Jiansheng Wang, email: wangjsh@mail.xjtu.edu.cn

Jia Zhang, email: zhangjiaxjtu@xjtu.edu.cn

Keywords: breast cancer, MYC, prognosis, clinicopathology, meta-analysis

Received: July 21, 2017    Accepted: August 31, 2017    Published: October 05, 2017

ABSTRACT

Background: Proto-oncogene MYC has been indicated to promote progression of many cancers. However, prognostic and clinicopathological significance of MYC in breast cancer need further evaluation.

Methods: We searched EMBASE and PubMed databases to find useful studies. We analyzed relationships between high MYC expression and prognostic data/ clinicopathological features through hazard ratio (HR) and odds ratio (OR). Each statistical test was two-sided.

Results: There were 29 studies (36 cohorts) with 12621 patients enrolled in our study The MYC overexpression was associated with worse DFS/RFS (disease/relapse free survival) in 11 studies (16 cohorts) with 5390 patients, and OS (overall survival) of 7 studies (8 cohorts) with 2672 patients. Subgroup analysis according to ethnicity/technique/data source displayed that MYC overexpression was associated with poor DFS/RFS in FISH, other technique, all data source and Asian/Non-Asian subgroup, and worse OS in all subgroups. In addition, MYC overexpression was related to large tumor size, high histologic grade, lymph node metastasis, negative hormone receptors and positive Ki67 expression.

Conclusions: Our results showed that MYC overexpression was associated with worse prognosis and high risk of breast cancer, especially in patients with negative hormone receptors, which highlighted the potential of MYC as a significant prognostic biomarker of breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21501